Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$6.54 USD
-0.42 (-6.03%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $6.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Cogent Biosciences, Inc. (COGT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$17.00 | $26.00 | $8.00 | 144.25% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Cogent Biosciences, Inc. comes to $17.00. The forecasts range from a low of $8.00 to a high of $26.00. The average price target represents an increase of 144.25% from the last closing price of $6.96.
Analyst Price Targets (11)
Broker Rating
Cogent Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.45 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on 10 recommendations.
Of the 11 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 72.73% and 9.09% of all recommendations. A month ago, Strong Buy made up 70%, while Buy represented 10%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 7 | 7 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.45 | 1.45 | 1.50 | 1.50 | 1.30 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/27/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Strong Buy |
2/26/2024 | Robert W. Baird & Co. | Colleen M Kusy | Not Available | Hold |
2/23/2024 | Wedbush Securities | David M Nierengarten | Hold | Hold |
2/22/2024 | SVB Securities | Andrew Berens | Not Available | Strong Buy |
1/2/2024 | Guggenheim Securities | Michael Schmidt | Not Available | Strong Buy |
12/5/2023 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
11/2/2023 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
10/17/2023 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.45 |
ABR (Last week) | 1.45 |
# of Recs in ABR | 11 |
Average Target Price | $17.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | -0.50 |